Why Is NAD+ Central to Longevity and Aging Research?

Rather than being studied for one narrow effect, NAD+ shows up across mitochondrial bioenergetics research, sirtuin signaling studies (SIRT1, SIRT3), DNA repair and PARP pathway research, and metabolic disease and insulin-resistance studies — because all of these processes draw on the same underlying NAD+ availability.

This is what distinguishes NAD+ research from a typical single-pathway research peptide: its documented age-related decline (roughly 50% or more by age 60 versus young adults) is cited across neurodegenerative disease preclinical research and metabolic disease models as a shared contributing factor, not a single isolated finding.

This describes published research literature on NAD+ biology and is provided for research background only — not a claim about any specific aging outcome or therapeutic benefit.